SCHEMBL3488032

SCHEMBL3488032

Nc1ccc(Oc2ccc(Cl)c(F)c2)cc1CNC(=O)O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 6/20 0.45
HTR2A P28223 5/20 0.45
KCNH2 Q12809 5/20 0.45
HIF1A Q16665 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
EGLN2 Q96KS0 1/20 0.40
EGLN1 Q9GZT9 1/20 0.40
ICAM1 P05362 1/20 0.39
SELE P16581 1/20 0.39
AKR1B1 P15121 1/20 0.38
CHEK2 O96017 1/20 0.38
SCN9A Q15858 1/20 0.37
CTSD P07339 1/20 0.36
BACE1 P56817 1/20 0.36
BRAF P15056 1/20 0.36
HDAC1 Q13547 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ATF4 P18848 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3487417 0.90 HTR2A (0.46) SLC6A4HTR2AKCNH2HIF1AAKR1B1
SCHEMBL3488807 0.88 SLC1A3 (0.45) HIF1APPARGPPARAAKR1B1SCN9A
SCHEMBL3487706 0.86 PPARG (0.41) SLC6A4HTR2AKCNH2PPARGPPARA
SCHEMBL3488332 0.84 GCK (0.46) PPARGPPARASCN9ABRAFHDAC1
SCHEMBL3487565 0.84 HTR2A (0.46) SLC6A4HTR2AKCNH2PPARGPPARA
SCHEMBL3488269 0.83 EGLN1 (0.42) HIF1APPARGPPARAEGLN1BRAF
SCHEMBL3488377 0.83 HIF1A (0.43) HIF1APPARGEGLN1AKR1B1SCN9A
SCHEMBL3487598 0.81 HTR2A (0.44) SLC6A4HTR2AKCNH2HIF1A
SCHEMBL3488176 0.80 TEAD4 (0.46)
SCHEMBL3487657 0.80 GCK (0.50) HIF1AEGLN2EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2138484-B1 FUSED BICYCLIC HETEROARYL DERIVATIVES DAIICHI SANKYO CO LTD (JP) 2015-08-26 EP disclosed
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2010-02-25 US disclosed
EP-2138484-A1 FUSED BICYCLIC HETEROARYL DERIVATIVES Daiichi Sankyo Company, Limited (JP) 2009-12-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048564-A1 FUSED BICYCLIC HETEROARYL DERIVATIVE PPARG, GPR119, PPARA SLC6A4 1449/4885HTR2A 1485/4885KCNH2 800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.